Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586725 | 1.00 | PTGS1 (0.33) | PTGS1PTGS2NOS1ALOX15BLM | |
| SCHEMBL4586739 | 1.00 | PTGS1 (0.33) | PTGS1PTGS2NOS1ALOX15BLM | |
| SCHEMBL4588055 | 1.00 | PTGS1 (0.33) | PTGS1PTGS2NOS1ALOX15BLM | |
| SCHEMBL4586699 | 0.84 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL4588735 | 0.84 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL4586713 | 0.84 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL4587335 | 0.84 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL5151428 | 0.79 | PTGS1 (0.37) | PTGS1PTGS2NOS1ALOX15BLM | |
| SCHEMBL5151041 | 0.74 | PTGS2 (0.42) | PTGS1PTGS2NOS1ALOX15BLM | |
| SCHEMBL5183569 | 0.74 | PTGS2 (0.42) | PTGS1PTGS2NOS1ALOX15BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | claimed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | PTGS1 83/4885PTGS2 177/4885NOS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.